Core Viewpoint - Recent breakthroughs in overseas clinical trials for aXess, an innovative medical device by Yuan Da Pharmaceutical, highlight its revolutionary potential in blood dialysis treatment for end-stage renal disease (ESRD) patients, marking a significant milestone in the company's "Go Global" strategy [1][2]. Group 1: Product Development and Clinical Trials - aXess is designed for establishing arteriovenous grafts for blood dialysis in ESRD patients, utilizing endogenous tissue repair (ETR) technology to enhance vascular recovery and reduce complications [2][3]. - The aXess EU clinical trial, conducted across 18 centers in Europe, aims to evaluate its patency, safety, and performance in patients requiring vascular access for dialysis [2][3]. - Clinical results indicate significant improvements in key clinical metrics compared to standard therapies, with lower re-intervention rates and a low incidence of bleeding complications [3]. Group 2: Market Potential and Demand - The global blood dialysis market reached approximately $94.43 billion in 2022, with projections to grow at a compound annual growth rate (CAGR) of about 6.8%, reaching $158.04 billion by 2030, indicating substantial market opportunities [3][6]. - In China, the number of patients receiving dialysis was around 844,300 in 2022, with an expected market size of nearly 48.4 billion yuan for dialysis-related equipment and consumables by 2030 [6]. Group 3: Strategic Positioning and Future Plans - Yuan Da Pharmaceutical's success with aXess is part of its broader strategy in the cardiovascular precision intervention sector, which includes over 30 products, with 22 approved for market in China [7][9]. - The company is actively pursuing global collaborations and innovation in product development, aiming to establish itself as a leading platform for cardiovascular precision interventions [10].
剑指千亿美元蓝海市场 远大医药球创新人工血管海外关键性临床获得突破性进展 “Go Global”战略行稳致远